Outpatient Microdose Induction with Transdermal Buprenorphine: A Case Series.

Transdermal buprenorphine is FDA approved for chronic severe pain but has an increasing amount of data supporting its use to transition patients from full opioid agonists to sublingual buprenorphine via a microdose strategy. The literature has primarily focused on patients with a pain diagnosis or who have been prescribed opioids in inpatient units. This case series reviews the use of transdermal buprenorphine to transition patients from methadone and illicit opioids to sublingual buprenorphine. The authors identified seven patients from an outpatient opiate treatment program who received the transdermal buprenorphine protocol. All patients were prescribed methadone and used illicit heroin prior to and during the transition. Five patients (71.4%) successfully completed the transition to sublingual buprenorphine, with all five patients reporting no or mild withdrawal symptoms. These findings suggest that transdermal buprenorphine is a potentially safe and effective microdose induction method for patients who use illicit substances in an outpatient setting.